Dr. Marshall explains procedures MedStar and Georgetown have instituted to ensure your safety while you receive the best care possible
Search our current GI clinical trials offered through the MedStar Georgetown Cancer Institute
Dr. Marshall talks with Today Show about why colon cancer is on the rise in young patients
Learn more about this year’s event on Monday, August 10, 2020
Dr. John L. Marshall addresses some of the questions he and his Georgetown Lombardi colleagues have been hearing most often from current cancer patients and survivors. Learn More
Gastrointestinal (GI) Cancers are the most common and most fatal of all cancers. The Ruesch Center will re-focus national efforts on curing this deadly set of diseases.
Georgetown Lombardi Clinical Trial Helps Advance Use of Immunotherapy in Liver Cancer
May 29th, 2020
In August of 2016, Dan Hilton arrived at MedStar Georgetown University Hospital to be evaluated for a liver transplant. He had been diagnosed with cirrhosis, the result of a hepatitis C infection contracted many years earlier. After multiple tests, he received unexpected news; the doctors found tumors on his liver.
Indivumed Global Alliance to Broaden Access to Multi-Omics Algorithms, Precision Medicine Education
May 4th, 2020
Germany-based Indivumed is enlisting the help of cancer centers and research institutions around the world to help expand its omics database and make it a key resource for unraveling the complexities of cancer biology and advancing new precision oncology drugs. Indivumed last month launched the Oncology Alliance for Individualized Medicine (Onco AI-Med), which is a partnership between leading cancer clinics and research institutions selected based on their research activities and expertise in molecularly informed cancer care. Currently, the collaboration includes over 30 partners from 11 countries, though Indivumed plans to add new sites to the alliance continuously.
Colorectal cancer care in the age of coronavirus: strategies to reduce risk and maintain benefit
April 16th, 2020
We are in unprecedented times requiring us to approach our medical obligations in unprecedented ways. Cancer care is not elective and therefore must be maintained throughout the COVID-19 pandemic. However, we recognize that there is early evidence based on small studies from China and Italy that cancer patients are at increased risk of severe illness if they are to develop a COVID-19 infection and there is even some evidence to suggest that healthcare providers are at increased risk, possibly due to exposure to larger viral loads and repeated exposure…
Sign Up to receive all Ruesch updates directly in your Inbox
We will deliver our quarterly newsletter, monthly updates and other announcements to your Inbox with information on upcoming special events, current clinical trials and cutting edge research and trends in the GI cancer field.
